General
Preferred name
PROPOXYCAINE
Synonyms
PROPOXYCAINE HYDROCHLORIDE ()
Propoxycaine HCl ()
Propoxycaine ()
Propoxycaine (hydrochloride) ()
NSC-760044 ()
Propoxicaina ()
P&D ID
PD008963
CAS
86-43-1
550-83-4
Tags
available
drug
Approved by
FDA
Drug Status
approved
withdrawn
Max Phase
4.0
First approval
1982
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Propoxycaine hydrochloride inhibits voltage-gated sodium channels, and thereby inhibits the ionic flux required for the initiation and conduction of impulses. Propoxycaine hydrochloride application can lead to a loss of sensation.
PRICE
46
MOA
Propoxycaine is a para-aminobenzoic acid ester with local anesthetic activity. Propoxycaine binds to and blocks voltage-gated sodium channels, thereby inhibiting the ionic flux essential for the conduction of nerve impulses. This results in a loss of sensation [L1588].; ; In one study, propoxycaine hydrochloride increased annular lipid fluidity in cell lipid bilayers and had a greater fluidizing effect on the inner monolayer than that of the outer monolayer [A32089]. This may further confirm its role in modulating neural impulses.
INDICATION
Propoxycaine is a local anesthetic medication. It was used beginning in the 1950s during dental procedures [L1591]. It has been combined with procaine to accelerate its onset of action and provide longer-lasting anesthetic effect [L1592].; ; It was produced for use when amide local anesthetics were contraindicated due to allergy or when several amide anesthetics were unsuccessful [L1592].
TOXICITY
The toxicity of this medication (7-8 times higher than that of procaine), has prevented this medication from being used on its own [L1592]. ; ; Ester-type local anesthetics are much more likely to cause an allergic reaction compared to the amide-group local anesthetics because of the formation of PABA (Para-aminobenzoic acid) during the metabolic process. PABA may cause allergic reactions that range from urticaria to anaphylaxis. PABA is also formed during the metabolism of methylparaben (a common preservative) that is normally found in multi-dose vials including lidocaine (MDV) (amide-type local anesthetic) [L1592, L1593].
DESCRIPTION
Propoxycaine hydrochloride, an ester local anesthetic, inhibits voltage-gated sodium channels, modulates nerve impulses, and can induce sensory loss.Propoxycaine hydrochloride modulates the flow of lipid bilayers in SPMVs.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
15
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
MedChem Express Bioactive Compound Library
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
41
Molecular Weight
294.19
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
9
Ring Count
1
Aromatic Ring Count
1
cLogP
2.56
TPSA
64.79
Fraction CSP3
0.56
Chiral centers
0.0
Largest ring
6.0
QED
0.56
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Sodium Channel
Indication
anesthetic
MOA
local anesthetic
ATC
N
Pathway
Membrane Transporter/Ion Channel
Source data
